---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-215435"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2025-09-24T23:59:59+00:00"
generated_at: "2026-05-17T05:48:33.424445+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PepGen reports 53.7% mean splicing correction in DM1 patients at 15 mg/kg dose

## Summary
- Mean splicing correction of 53.7% at 15 mg/kg (n=6) by 22-gene panel at Day 28; all 6 patients responded.
- PGN-EDODM1 well-tolerated; no serious treatment-related AEs, all mild/moderate, transient, resolved without intervention.
- Dose-proportional muscle concentration increase vs 5 mg/kg (12.3%) and 10 mg/kg (29.1%) cohorts.
- FREEDOM2 MAD study 5 mg/kg cohort data expected Q1 2026; 10 mg/kg cohort dosing to begin Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-215435
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2025-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000119312525215435/0001193125-25-215435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000119312525215435/d67598d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-215435
- JSON: https://secwatch.observer/filing/0001193125-25-215435.json
- Plain text: https://secwatch.observer/filing/0001193125-25-215435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.